Liraglutide (Saxenda) was the first GLP-1 receptor agonist approved by the FDA specifically for chronic weight management, receiving approval in December 2014. Semaglutide (Wegovy) followed in 2021 with substantially higher average weight loss in clinical trials. The two drugs share the same mechanism, GLP-1 receptor agonism, but differ in potency, dosing frequency, and efficacy. For patients who used liraglutide before semaglutide was available, or who are evaluating options, understanding the differences is practical.
Mechanism and Structural Differences
Both drugs are GLP-1 receptor agonists. They activate the same receptors in the brain, gut, and pancreas to suppress appetite, slow gastric emptying, and improve insulin sensitivity. The structural differences, liraglutide is derived from human GLP-1 with a fatty acid chain, semaglutide has a different fatty acid chain and an amino acid substitution, produce dramatically different half-lives.
Liraglutide has a half-life of approximately 13 hours and requires daily subcutaneous injection. Semaglutide’s half-life is approximately 165-184 hours (about seven days) and is injected once weekly. This pharmacokinetic difference is the primary driver of the different efficacy profiles, once-weekly semaglutide maintains higher and more consistent GLP-1 receptor stimulation than once-daily liraglutide.
Clinical Trial Comparison
The key trial for liraglutide weight loss was the SCALE trial program. The SCALE Obesity and Prediabetes trial, published in NEJM in 2015, enrolled 3,731 adults with BMI 30 or higher and randomized them to 3 mg daily liraglutide or placebo for 56 weeks. The liraglutide group lost an average of 8.4% of body weight versus 2.8% for placebo.
The key trial for semaglutide weight loss (STEP-1) produced average weight loss of 14.9% at 68 weeks in a similar patient population.
This places semaglutide at roughly 1.75 times the average weight loss of liraglutide in comparable patient populations. Neither drug has been directly head-to-head in a randomized trial using the approved doses for weight loss, but the separate trial data and magnitude of difference make semaglutide’s superior efficacy essentially uncontested in the clinical community.
Side Effect Comparison
The side effect profiles are qualitatively similar, primarily gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal discomfort. Both are dose-dependent and most pronounced during dose escalation.
Liraglutide’s daily injection frequency means the body experiences a daily peak and trough in drug levels, and nausea may recur daily in some patients. Semaglutide’s weekly peak is followed by a steady decline; nausea associated with peak drug levels occurs once weekly rather than daily.
In clinical experience, semaglutide’s nausea is often described as more manageable than liraglutide’s for this reason, though individual response varies.
Cost Comparison
Saxenda (liraglutide 3 mg) lists at approximately $1,350 per month, similar to Wegovy’s list price. Compounded liraglutide has been less widely available than compounded semaglutide, partly because semaglutide achieved FDA shortage designation that facilitated compounding.
Who Might Still Use Liraglutide
With semaglutide providing superior efficacy at similar cost, liraglutide’s role has narrowed. It remains relevant for:
Children 12+: Liraglutide (Saxenda) received FDA approval for adolescents aged 12 and older in 2020, before semaglutide had pediatric approval. Semaglutide subsequently received approval for adolescents 12+, reducing even this distinction.
Patients who tolerate liraglutide but not semaglutide: Because the drugs activate the same receptor at the same sites, patients who do not tolerate one often do not tolerate the other. But occasional patients find one more manageable than the other.
Availability: In markets where semaglutide remains on shortage or compounded semaglutide is legally unavailable, liraglutide may be the accessible option.
For an overview of the GLP-1 drug class and how they compare, see What Is Semaglutide and How Does It Work for Weight Loss? and Tirzepatide vs. Semaglutide: What the Clinical Trials Actually Show.
